A retrospective cohort study identified real-world epidemiology, treatment patterns, and survival outcomes in patients with multiple myeloma (MM) in Israel. The findings were reported in Leukemia Research.
The study was conducted using databases from Maccabi Healthcare Services, a nationwide health plan in Israel that accounts for a quarter of the country’s population. The prevalence of MM was determined by assessing the number of health plan members with MM who were alive at the end of the study period, which was December 31, 2016. The incidence of MM was determined via the number of health plan members who received a new diagnosis of MM between 2012 and 2016.
On December 31, 2016, a total of 663 health plan members were found to have MM, which translated to a prevalence rate of 3.2 cases per 10,0000 people. The age-standardized prevalence rate was 2.6 cases per 10,0000 people.